Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
PLoS One ; 16(9): e0257319, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34582473

RESUMEN

INTRODUCTION: Complementary and alternative medicine (CAM) is frequently used by patients with rheumatic diseases (RD) to improve their symptoms; however, its diversity and availability have increased notably while scientific support for its effectiveness and adverse effects is still scarce. OBJECTIVE: To describe the prevalence and diversity of CAM in patients with RD in Chihuahua, Mexico. METHODS: A cross-sectional study was conducted in 500 patients with RD who were interviewed about the use of CAM to treat their disease. The interview included sociodemographic aspects, characteristics of the disease, as well as a description of CAM use, including type, frequency of use, perception of the benefit, communication with the rheumatologist, among others. RESULTS: The prevalence of CAM use was reported by 59.2% of patients, which informed a total of 155 different therapies. The herbal CAM group was the most used (31.4%) and included more than 50 different therapies. The use of menthol-based and arnica ointments was highly prevalent (35%). Most patients (62.3%) reported very little or no improvement in their symptoms. Only a fourth of the patients informed the rheumatologist of the use of CAM. The use of CAM was influenced by female sex, university degree, diagnosis delay, lack adherence to the rheumatologist's treatment, family history of RD, and orthopedic devices. CONCLUSION: The use of CAM in our population is highly prevalent and similar to reports in different populations suggesting a widespread use in many different societies. We found high use of herbal remedies; however, there were many different types suggesting a lack of significant effect. Patients continue using CAM despite a perception of no-effectiveness. Recurrent use of CAM is explained by factors other than its efficacy.


Asunto(s)
Terapias Complementarias/estadística & datos numéricos , Enfermedades Reumáticas/terapia , Adulto , Estudios Transversales , Femenino , Humanos , Masculino , México , Persona de Mediana Edad , Aceptación de la Atención de Salud , Percepción , Relaciones Médico-Paciente , Fitoterapia , Prevalencia , Encuestas y Cuestionarios , Resultado del Tratamiento , Revelación de la Verdad
2.
Reumatol Clin ; 8(4): 168-73, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22704914

RESUMEN

BACKGROUND: The cost of certain diseases may lead to catastrophic expenses and impoverishment of households without full financial support by the state and other organizations. OBJECTIVE: To determine the socioeconomic impact of the rheumatoid arthritis (RA) cost in the context of catastrophic expenses and impoverishment. PATIENTS AND METHODS: This is a cohort-nested cross-sectional multicenter study on the cost of RA in Mexican households with partial, full, or private health care coverage. Catastrophic expenses referred to health expenses totaling >30% of the total household income. Impoverishment defined those households that could not afford the Mexican basic food basket (BFB). RESULTS: We included 262 patients with a mean monthly household income (US dollars) of $376 (0­18,890.63). In all, 50.8%, 35.5%, and 13.7% of the patients had partial, full, or private health care coverage, respectively. RA annual cost was $ 5534.8 per patient (65% direct cost, 35% indirect). RA cost caused catastrophic expenses in 46.9% of households, which in the logistic regression analysis were significantly associated with the type of health care coverage (OR 2.7, 95%CI 1.6­4.7) and disease duration (OR 1.024, 95%CI 1.002­1.046). Impoverishment occurred in 66.8% of households and was associated with catastrophic expenses (OR 3.6, 95%CI 1.04­14.1), high health assessment questionnaire scores (OR 4.84 95%CI 1.01­23.3), and low socioeconomic level (OR 4.66, 95%CI 1.37­15.87). CONCLUSION: The cost of RA in Mexican households, particularly those lacking full health coverage leads to catastrophic expenses and impoverishment. These findings could be the same in countries with fragmented health care systems.


Asunto(s)
Artritis Reumatoide/economía , Costo de Enfermedad , Gastos en Salud , Pobreza , Adulto , Antiinflamatorios/economía , Antiinflamatorios/uso terapéutico , Antirreumáticos/economía , Antirreumáticos/uso terapéutico , Enfermedad Catastrófica/economía , Estudios de Cohortes , Estudios Transversales , Familia , Femenino , Abastecimiento de Alimentos/economía , Humanos , Renta/estadística & datos numéricos , Seguro de Salud , Masculino , Pacientes no Asegurados , México , Persona de Mediana Edad , Programas Nacionales de Salud/economía , Sector Privado/economía , Calidad de Vida , Seguridad Social/economía , Encuestas y Cuestionarios , Adulto Joven
3.
Reumatol Clin ; 7 Suppl 3: S28-32, 2011 Dec.
Artículo en Español | MEDLINE | ID: mdl-22152287

RESUMEN

Large vessels vasculitis: Giant cells arteritis (GCA), and Takayasu's arteritis (TA) are a pair of systemic chronic inflammatory diseases characterized by specific involvement of large caliber, elastic-layered arteries. Presently, and derived from the paucity of clinical controlled trials approaching the issue, the management of GCA and TA is largely based on the clinical judgment of the treating physician. Glucocorticoids and immunosuppressive drugs are used when clear evidence of inflammatory activity is observed. The traditional management approach is to start with systemic glucocorticoid therapy at immunosuppressive dose, followed by cytotoxic immunosuppressive drugs (methotrexate, azatioprine, cyclophosphamide or mycofenolate mofetil) aimed at maintaining remission and decreasing corticosteroid therapy time. Recently, based on the potential pathogenic role of tumor necrosis factor α in these diseases, a series of reports addressing the benefic effect of αTNF-blockers in patients who have been resistant to the traditional management approach have been published. Non- reversible vascular lesions (such as occlusion or stenosis) may require surgical treatment (stent or bypass), however this must be done only when a complete control of the inflammatory activity has been reached.


Asunto(s)
Antiinflamatorios/uso terapéutico , Arteritis/tratamiento farmacológico , Inmunosupresores/uso terapéutico , Arteritis/cirugía , Terapia Biológica , Implantación de Prótesis Vascular , Conservadores de la Densidad Ósea/uso terapéutico , Terapia Combinada , Quimioterapia Combinada , Arteritis de Células Gigantes/tratamiento farmacológico , Arteritis de Células Gigantes/cirugía , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Humanos , Osteoporosis/inducido químicamente , Osteoporosis/prevención & control , Guías de Práctica Clínica como Asunto , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto , Stents , Arteritis de Takayasu/tratamiento farmacológico , Arteritis de Takayasu/cirugía , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
4.
Reumatol. clín. (Barc.) ; 7(supl.3): s28-s32, dic. 2011. tab
Artículo en Español | IBECS | ID: ibc-147314

RESUMEN

Las vasculitis primarias de grandes vasos: la arteritis de células gigantes (ACG) y la arteritis de Takayasu (AT) son enfermedades inflamatorias crónicas que afectan principalmente las arterias elásticas de gran calibre. En la actualidad hay escasas evidencias que permitan conocer cuál es el mejor tratamiento en cuanto a eficacia y seguridad, así como la mejor estrategia para mantener la remisión y mejorar el pronóstico debido a que casi no hay estudios controlados sobre el tópico, por lo que en la mayoría de los casos el tratamiento se basa en el juicio del clínico. Los glucocorticoides e inmunosupresores están indicados si hay una clara evidencia de actividad. El enfoque tradicional consiste en el uso de glucocorticoides a dosis inmunosupresoras para el manejo de los episodios de actividad inflamatoria, seguido de inmunosupresores citotóxicos (metotrexato, azatioprina, ciclofosfamida o micofenolato de mofetilo) para mantener la remisión y disminuir el tiempo en corticoterapia. En fechas recientes, y dado el papel patogénico potencial del factor de necrosis tumoral en estos padecimientos, hay reportes alentadores del uso de inhibidores de esta citocina en el tratamiento de pacientes refractarios al enfoque tradicional. Las lesiones que dejan como secuela oclusión o estenosis vascular habitualmente no son reversibles con el tratamiento médico, por lo que en ocasiones requieren de tratamiento quirúrgico (angioplastia o bypass), el cual debe realizarse solo cuando la actividad de la enfermedad esté controlada de forma adecuada (AU)


Large vessels vasculitis: Giant cells arteritis (GCA), and Takayasu’s arteritis (TA) are a pair of systemic chronic inflammatory diseases characterized by specific involvement of large caliber, elastic-layered arteries. Presently, and derived from the paucity of clinical controlled trials approaching the issue, the management of GCA and TA is largely based on the clinical judgment of the treating physician. Glucocorticoids and immunosuppressive drugs are used when clear evidence of inflammatory activity is observed. The traditional management approach is to start with systemic glucocorticoid therapy at immunosuppressive dose, followed by cytotoxic immunosuppressive drugs (methotrexate, azatioprine, cyclophosphamide or mycofenolate mofetil) aimed at maintaining remission and decreasing corticosteroid therapy time. Recently, based on the potential pathogenic role of tumor necrosis factor in these diseases, a series of reports addressing the benefic effect of TNF-blockers in patients who have been resistant to the traditional management approach have been published. Non- reversible vascular lesions (such as occlusion or stenosis) may require surgical treatment (stent or bypass), however this must be done only when a complete control of the inflammatory activity has been reached (AU)


Asunto(s)
Humanos , Antiinflamatorios/uso terapéutico , Arteritis/tratamiento farmacológico , Arteritis/cirugía , Inmunosupresores/uso terapéutico , Conservadores de la Densidad Ósea/uso terapéutico , Osteoporosis/inducido químicamente , Osteoporosis/prevención & control , Stents , Terapia Biológica , Implantación de Prótesis Vascular , Terapia Combinada , Arteritis de Células Gigantes/tratamiento farmacológico , Arteritis de Células Gigantes/cirugía , Glucocorticoides/efectos adversos , Glucocorticoides/uso terapéutico , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto , Arteritis de Takayasu/tratamiento farmacológico , Arteritis de Takayasu/cirugía , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
5.
Reumatol Clin ; 2(4): 183-9, 2006 Jul.
Artículo en Español | MEDLINE | ID: mdl-21794326

RESUMEN

OBJECTIVES: To determine the frequency of the use of complementary and alternative medicine (CAM) in patients attending a rheumatology department in a general hospital for the first time. SUBJECTS AND METHODS: We included consecutive patients attending our rheumatology department for the first time. All the patients completed a self-administered questionnaire containing items on demographic data, and prior diagnosis. The patients were also given a list of 22 different CAM and marked those they had previously used. RESULTS: Eight hundred patients were studied. Eighty percent were women. The mean age was 44.8±14.9 years and the mean number of years of education was 7±4. The main diagnoses were osteoarthritis (29.4%), rheumatoid arthritis (22.3%), and fibromyalgia (6.5%). Seventy-one percent had previously used CAM, with a median of two (0-14) different types. The most common were vitamin supplements (38%), arnica (18%), Aloe vera (15%) and homeopathy (15%). No significant differences were found in sex, age, educational level, or diagnosis. The use of CAM was more frequent in patients with longer disease duration. CONCLUSIONS: The frequency of use of CAM is high in patient with rheumatologic manifestations.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA